Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 12:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Androgen Suppression Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery

NCT03070886
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions
Bicalutamide, Degarelix, Docetaxel, External Beam Radiation Therapy, Flutamide, Goserelin, Goserelin Acetate, Laboratory Biomarker Analysis, Leuprolide, Leuprolide Acetate, Nilutamide
Drug · Radiation · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
612 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
311
States / cities
Mobile, Alabama • Fairbanks, Alaska • Phoenix, Arizona + 254 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Recruiting Not applicable Interventional

Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients

NCT06824818
View directory record Official record
Conditions
Elderly, Prostate Cancer
Interventions
LHRH Agonist Therapy Discontinuation
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
70 Years and older · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Phase 2 Interventional Results available

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

NCT04523207
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Apalutamide, ADT, Relugolix
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
32
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sherman Oaks, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

NCT04737109
View directory record Official record
Conditions
Castrate Resistant Prostate Cancer
Interventions
Ipatasertib, Darolutamide, Androgen Deprivation Therapy
Drug
Lead sponsor
David VanderWeele
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • Indianapolis, Indiana • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Phase 1 Interventional

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

NCT02064036
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Stereotactic Radiosurgical Boost, Casodex, Leuprolide
Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 28, 2026, 12:04 PM EDT
Terminated Phase 2 Interventional Results available

Enzalutamide for Bladder Cancer Chemoprevention

NCT02605863
View directory record Official record
Conditions
Bladder Cancer
Interventions
Enzalutamide
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 28, 2026, 12:04 PM EDT
Recruiting Phase 2 Interventional

Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)

NCT07224009
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
Naltrexone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Not applicable Interventional Results available

Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer

NCT01542021
View directory record Official record
Conditions
Prostate Cancer, Prostatic Adenocarcinoma
Interventions
degarelix injection, androgen deprivation therapy
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Terminated Phase 2 Interventional Results available

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

NCT02582749
View directory record Official record
Conditions
Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions
LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride
Drug · Radiation
Lead sponsor
Ajjai Alva, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
12
States / cities
Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2022 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

A Trial of Degarelix in Patients With Prostate Cancer

NCT00946920
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Goserelin acetate
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Homewood, Alabama • Little Rock, Arkansas • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 28, 2026, 12:04 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

NCT03419234
View directory record Official record
Conditions
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Abiraterone Acetate, Androgen deprivation therapy, Cabazitaxel, Prednisone
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Male only
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
665
States / cities
Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Not applicable Interventional

RESIST-ADT (Androgen Deprivation Therapy)

NCT04485767
View directory record Official record
Conditions
Prostate Cancer, Physical Function
Interventions
Progressive Resistance Training Exercise, Flexibility and Balance Exercise
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
60 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 28, 2026, 12:04 PM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Chemohormonal Therapy Followed by Salvage Surgery for High Risk PSA

NCT01531205
View directory record Official record
Conditions
Prostate Cancer
Interventions
Androgen Ablation, Cabazitaxel, Salvage Therapy, Neoadjuvant Treatment - Hormonal Therapy, Neoadjuvant Treatment - Cabazitaxel
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 28, 2026, 12:04 PM EDT
Recruiting Phase 2 Interventional

Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer

NCT07364071
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Radiation therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Recruiting Phase 2 Interventional

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

NCT07210086
View directory record Official record
Conditions
Prostate Cancer
Interventions
ADT, ARSI, No ADT/ARSI -decline
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Not applicable Interventional

A Prostate Cancer Study in Men Undergoing Androgen Deprivation Therapy

NCT00087659
View directory record Official record
Conditions
Prostate Cancer
Interventions
zoledronic acid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
16
States / cities
Tucson, Arizona • Long Beach, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2009 · Synced Sep 28, 2026, 12:04 PM EDT
Active, not recruiting Phase 2 Interventional

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer

NCT03456843
View directory record Official record
Conditions
Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Docetaxel, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Radical Prostatectomy
Drug · Other · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
7
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 28, 2026, 12:04 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

External Beam Radiation With or Without Chemotherapy to Treat High Risk Prostate Cancer

NCT01603420
View directory record Official record
Conditions
Prostate Cancer
Interventions
Luteinizing hormone-releasing hormone (LHRH), Docetaxel, Conformal Radiation Therapy (RT)
Drug · Other
Lead sponsor
Proton Collaborative Group
Network
Eligibility
18 Years to 75 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Warrenville, Illinois • Oklahoma City, Oklahoma • Hampton, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 28, 2026, 12:04 PM EDT
Completed Not applicable Interventional

PROWESS (PROstate Cancer Wearables Exercise and Structured Supports): A Pilot Supportive Care Intervention

NCT05755490
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasms
Interventions
PROWESS
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 28, 2026, 12:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

NCT04989946
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, pTVG-AR, Nivolumab, Cemiplimab, Fianlimab, FLT PET/CT
Drug · Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Recruiting Not applicable Interventional

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life

NCT06171269
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, MRI, Androgen Deprivation Therapy
Radiation · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Active, not recruiting Phase 2 Interventional

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

NCT06212583
View directory record Official record
Conditions
Prostate Cancer, Oligometastatic Disease
Interventions
niraparib/abiraterone acetate, Stereotactic ablative radiation therapy (SABR), Androgen deprivation therapy (ADT)
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older · Male only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 28, 2026, 12:04 PM EDT
Terminated Phase 1Phase 2 Interventional

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

NCT02805894
View directory record Official record
Conditions
Prostate Cancer
Interventions
NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
Drug
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2021 · Synced Sep 28, 2026, 12:04 PM EDT